Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States

By sjmartinez • January 7, 2023

Nicholas SB, Alicic RZ, Shen J. Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States. Kidney Med. 2022 Dec 15;5(1):100590. doi: 10.1016/j.xkme.2022.100590. PMID: 36605084; PMCID: PMC9807823.

Tags: Harbor UCLA, Nephrology, Publications

Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV

Crothers K, Nance RM, Whitney BM, Harding BN, Heckbert SR, Budoff MJ, Mathews WC, Bamford L, Cachay ER, Eron JJ, Napravnik S, Moore RD, Keruly ...

Calcium intake and lung cancer risk: a pooled analysis of 12 prospective cohort studies

Takata Y, Yang JJ, Yu D, Smith-Warner SA, Blot WJ, White E, Robien K, Prizment A, Wu K, Sawada N, Lan Q, Park Y, Gao ...

Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants

Kurihara C, Sakurai R, Chuang TD, Waring AJ, Walther FJ, Rehan VK. Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung ...